Start with chronic obstructive pulmonary disease, then reuse UniProt P34913 as the stable protein anchor across project notes and exports.
CHEMBL2409 Target Snapshot
Bifunctional epoxide hydrolase 2 · SINGLE PROTEIN · Homo sapiens
Research home keeps recent targets
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Switch target
Move to another high-traffic target or paste a specific ChEMBL target ID.
Frame the target before identity details
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-14Bifunctional epoxide hydrolase 2 shows clinical signal disease relevance led by chronic obstructive pulmonary disease. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P34913. Start with chronic obstructive pulmonary disease, then reuse UniProt P34913 as the stable protein anchor across project notes and exports.
Bifunctional epoxide hydrolase 2 shows clinical signal disease relevance led by chronic obstructive pulmonary disease. 1 linked drug remains visible in the same block.
Start review with chronic obstructive pulmonary disease because it currently carries clinical signal support. Linked drugs include GSK2256294. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyBifunctional epoxide hydrolase 2
Review this target as Bifunctional epoxide hydrolase 2, mapped to UniProt P34913. Sequence length is 555 aa.
Protein source · UniProt accession via ChEMBL component mappingCross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Bifunctional epoxide hydrolase 2 as ChEMBL target CHEMBL2409, mapped to UniProt P34913. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Start with the right source
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether Bifunctional epoxide hydrolase 2 is the right protein anchor across sources, using UniProt P34913 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why chronic obstructive pulmonary disease is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardBasic Information
Verify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | Bifunctional epoxide hydrolase 2 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | P34913 |
Next Actions
UniProt Target Context
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | Bifunctional epoxide hydrolase 2 |
| UniProt Accession | P34913 |
| Component Type | Protein |
| Sequence Length | 555 aa |
Bifunctional epoxide hydrolase 2
How to read this target
Review this target as Bifunctional epoxide hydrolase 2, mapped to UniProt P34913. Sequence length is 555 aa.
Disease Relevance & Evidence Level
Open Targets-ready disease context using the current target-indication evidence contract.
Bifunctional epoxide hydrolase 2 shows clinical signal disease relevance led by chronic obstructive pulmonary disease.
How to read disease relevance
Start review with chronic obstructive pulmonary disease because it currently carries clinical signal support. Linked drugs include GSK2256294. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Clinical Phase Distribution
Activity Type Distribution
Top Inhibitors (by pChEMBL)
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL3327073 | 10.7 | Ki | 0.02 | Preclinical |
| CHEMBL3818875 | 10.57 | IC50 | 0.027 | Clinical |
| CHEMBL5190894 | 10.52 | IC50 | 0.03 | Preclinical |
| CHEMBL5425833 | 10.3 | IC50 | 0.05 | Preclinical |
| CHEMBL5746598 | 10.3 | Ki | 0.05 | Preclinical |
| CHEMBL5891245 | 10.3 | Ki | 0.05 | Preclinical |
| CHEMBL6038062 | 10.22 | Ki | 0.06 | Preclinical |
| CHEMBL4752831 | 10.1 | Ki | 0.08 | Preclinical |
| CHEMBL4745610 | 10.09 | IC50 | 0.082 | Preclinical |
| CHEMBL4781218 | 10.0 | IC50 | 0.1 | Preclinical |
pChEMBL Value Distribution
Approved Drugs
Assay Landscape
Binding — 273 assays, 2,893 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 190 | 2,043 | 7.6 |
| cell-based format | 59 | 303 | 7.5 |
| assay format | 21 | 487 | 7.8 |
| organism-based format | 1 | 59 | 8.5 |
| subcellular format | 1 | 0 | — |
| tissue-based format | 1 | 1 | 8.2 |
ADME — 1 assays, 0 compounds
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| subcellular format | 1 | 0 | — |